SARASOTA, Fla., Jan. 17 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation today announced that Mark Truei, Ph.D., has been hired as Vice President of Production and Manufacturing.
Dr. Truei has extensive hands-on experience in pharmaceutical and biotechnology R&D, process development and manufacturing, and in-depth knowledge in pharmaceutical and biotechnology process technologies and scale- up. He has successfully executed and managed many bio-pharmaceutical facility design and process consulting projects, and has successfully managed many bio- pharmaceutical facility design projects worldwide.
Before joining IBTY, he held several executive and managerial positions, including: Vice President of China Operations at Arena Pharmaceuticals, Director of Business Development at Kinetics Biopharm, Director of Technology and Bioprocesses at CDI, Managing Director at Pharmaplan Hatch and Project Manager at Raytheon Engineers & Constructors, where he oversaw and led process and facility projects from Merck & Co., Inc., Pfizer Inc., Serono Laboratories, Roche Carolina Inc., Sandoz Inc., Lederle-Praxis, Eisai USA, etc.
Dr. Truei holds several degrees and distinctions including a Ph.D. in Chemical Engineering from Purdue University with the thesis area in bio- separation engineering, an M.S. in Applied Chemistry from Yale University with the thesis area in bio-analytical chemistry and high-performance liquid chromatography, an M.S. in Chemical Engineering from National Taiwan University with the thesis area in cell culture & fermentation engineering, and a B.S. in Chemical Engineering from Tunghai University, plus a course Sequence Award in the Business of Biotechnology from the University of California, San Diego. In addition, he is a member of the American Association for the Advancement of Science, American Chemical Society, American Institute of Chemical Engineers, and International Society for Pharmaceutical Engineering (SIG Chair).
Dr Truei stated: “I am very pleased to be involved with Industrial Biotechnology Corporation. The biological production of chemicals is the future of the industry and will reinvent the way chemicals are manufactured, at lower production costs and safer for our environment. Our biological production methods will replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. Our proprietary patented technology involves fewer production steps and enables IBC to produce greater yields of high-purity, natural compounds at significantly lower costs.”
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high-value chemicals at significantly lower costs, with a substantially lower environmental impact than traditional methods, and with a higher purity. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC will bring to market new and established chemicals that are in high demand for use in Flavors, Fragrances and Fine Chemicals, and Pharmaceutical, Agricultural, Environmental and Bio-Energy applications. IBC’s pioneering and state-of-the-art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. These innovative methods involve fewer production steps and, through the use of “designer” enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled-up to large, commercial production levels. IBC’s core intellectual property utilizes patented technologies exclusively licensed from Rice University. The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and will seek to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable biological-based solutions and related intellectual property patents. For more information, email us: info@industrialbiotechnology.com
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words, such as “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation’s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Industrial Biotechnology Corporation
CONTACT: David L. West, Industrial Biotechnology Corporation,+1-941-925-2500
Web site: http://www.industrialbiotechnology.com/
